---
title: "Bank of America Securities Remains a Buy on Caribou Biosciences (CRBU)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286234091.md"
description: "Bank of America Securities analyst Alec Stranahan has maintained a Buy rating on Caribou Biosciences (CRBU) with a price target of $6.00, while the stock closed at $2.03. The analyst consensus is a Strong Buy with an average price target of $9.00, indicating a potential upside of 343.35%. H.C. Wainwright also supports this with a Buy rating and a price target of $11.00. Stranahan has an average return of 10.3% and a 52.78% success rate on his stock recommendations."
datetime: "2026-05-13T09:39:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286234091.md)
  - [en](https://longbridge.com/en/news/286234091.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286234091.md)
generator: "portal-rs"
---

# Bank of America Securities Remains a Buy on Caribou Biosciences (CRBU)

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Caribou Biosciences yesterday and set a price target of $6.00. The company’s shares closed yesterday at $2.03.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Stranahan covers the Healthcare sector, focusing on stocks such as Moderna, Beam Therapeutics, and Revolution Medicines. According to TipRanks, Stranahan has an average return of 10.3% and a 52.78% success rate on recommended stocks. 

Currently, the analyst consensus on Caribou Biosciences is a Strong Buy with an average price target of $9.00, which is a 343.35% upside from current levels. In a report released on May 11, H.C. Wainwright also maintained a Buy rating on the stock with a $11.00 price target.

### Related Stocks

- [CRBU.US](https://longbridge.com/en/quote/CRBU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [BEAM.US](https://longbridge.com/en/quote/BEAM.US.md)
- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [Caribou Biosciences Q2 net loss narrows](https://longbridge.com/en/news/295849330.md)
- [Analyst Reiterates Buy on Caribou, Citing Strong vispa-cel Data and Pivotal ANTLER-3 Upside; Price Target Maintained at $11](https://longbridge.com/en/news/289901578.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**